Navann Ty's Stock Ratings

Exane BNP Paribas Analyst

Navann Ty is an analyst at Exane BNP Paribas. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 06/30/2025

Overall Average Return

26.0%

Smart Score

68.7%

Overall Average Return Percentile

84th

Number of Ratings

39
Buy NowGet Alert
08/16/2023RVNCBuy Now
Revance Therapeutics
——
Navann Ty68%
→ $20UpgradeUnderperform → NeutralGet Alert
05/30/2023KVUEBuy Now
Kenvue
$20.8534.29%
Navann Ty68%
→ $28Initiates → NeutralGet Alert
03/22/2022ALKSBuy Now
Alkermes
$30.00-13.33%
Navann Ty68%
$22 → $26MaintainsNeutralGet Alert
03/10/2022VTRSBuy Now
Viatris
$9.0721.28%
Navann Ty68%
$16 → $11MaintainsNeutralGet Alert
03/09/2022ENDPBuy Now
Endo International
——
Navann Ty68%
$11 → $6MaintainsBuyGet Alert
12/20/2021ZTSBuy Now
Zoetis
$156.1748.56%
Navann Ty68%
$184 → $232MaintainsNeutralGet Alert
12/01/2021ALKSBuy Now
Alkermes
$30.00-26.67%
Navann Ty68%
→ $22Initiates → NeutralGet Alert
10/05/2021JAZZBuy Now
Jazz Pharmaceuticals
$106.9087.09%
Navann Ty68%
→ $200Initiates → BuyGet Alert
08/05/2021HZNPBuy Now
Horizon Therapeutics
——
Navann Ty68%
$117 → $121MaintainsBuyGet Alert
07/23/2021OGNBuy Now
Organon
$9.94252.11%
Navann Ty68%
→ $35Initiates → BuyGet Alert
07/22/2021OGNBuy Now
Organon
$9.94252.11%
Navann Ty68%
→ $35Initiates → BuyGet Alert
06/15/2021VTRSBuy Now
Viatris
$9.0776.41%
Navann Ty68%
→ $16Initiates → NeutralGet Alert
05/12/2021ZTSBuy Now
Zoetis
$156.1717.82%
Navann Ty68%
$175 → $184MaintainsNeutralGet Alert
03/18/2021HZNPBuy Now
Horizon Therapeutics
——
Navann Ty68%
→ $120MaintainsBuyGet Alert
08/27/2020HZNPBuy Now
Horizon Therapeutics
——
Navann Ty68%
→ $112Initiates → BuyGet Alert
08/10/2020ZTSBuy Now
Zoetis
$156.172.45%
Navann Ty68%
$146 → $160MaintainsNeutralGet Alert
07/30/2020ZTSBuy Now
Zoetis
$156.17-6.51%
Navann Ty68%
$131 → $146MaintainsNeutralGet Alert
05/01/2019ALKSBuy Now
Alkermes
$30.0010%
Navann Ty68%
$62 → $33DowngradeBuy → NeutralGet Alert
05/01/2019HZNPBuy Now
Horizon Therapeutics
——
Navann Ty68%
$21 → $32UpgradeNeutral → BuyGet Alert
05/01/2019HZNPBuy Now
Horizon Therapeutics
——
Navann Ty68%
—UpgradeNeutral → BuyGet Alert
07/10/2018JAZZBuy Now
Jazz Pharmaceuticals
$106.9091.77%
Navann Ty68%
$162 → $205MaintainsBuyGet Alert
06/27/2018HZNPBuy Now
Horizon Therapeutics
——
Navann Ty68%
—DowngradeBuy → NeutralGet Alert
05/16/2018ALKSBuy Now
Alkermes
$30.00—
Navann Ty68%
—UpgradeNeutral → BuyGet Alert
11/28/2016HZNPBuy Now
Horizon Therapeutics
——
Navann Ty68%
—ReinstatesNeutral → BuyGet Alert
09/27/2016ALKSBuy Now
Alkermes
$30.0076.67%
Navann Ty68%
$44 → $53MaintainsNeutralGet Alert
08/09/2016HZNPBuy Now
Horizon Therapeutics
——
Navann Ty68%
$18 → $21MaintainsNeutralGet Alert
04/25/2016HZNPBuy Now
Horizon Therapeutics
——
Navann Ty68%
$21 → $18MaintainsNeutralGet Alert
01/06/2016HZNPBuy Now
Horizon Therapeutics
——
Navann Ty68%
—Assumes → NeutralGet Alert
03/27/2015ALKSBuy Now
Alkermes
$30.00136.67%
Navann Ty68%
$83 → $71DowngradeBuy → NeutralGet Alert
03/02/2015HZNPBuy Now
Horizon Therapeutics
——
Navann Ty68%
$19 → $23MaintainsBuyGet Alert
02/25/2015ALKSBuy Now
Alkermes
$30.00176.67%
Navann Ty68%
$85 → $83MaintainsBuyGet Alert
01/14/2015ALKSBuy Now
Alkermes
$30.00183.33%
Navann Ty68%
$72 → $85MaintainsBuyGet Alert
12/17/2014ALKSBuy Now
Alkermes
$30.00140%
Navann Ty68%
$60 → $72MaintainsBuyGet Alert
11/05/2014JAZZBuy Now
Jazz Pharmaceuticals
$106.9088.96%
Navann Ty68%
$165 → $202MaintainsBuyGet Alert
05/09/2014JAZZBuy Now
Jazz Pharmaceuticals
$106.9054.35%
Navann Ty68%
$195 → $165MaintainsBuyGet Alert
03/12/2013JAZZBuy Now
Jazz Pharmaceuticals
$106.90-29.84%
Navann Ty68%
$70 → $75MaintainsBuyGet Alert
01/15/2013ALKSBuy Now
Alkermes
$30.00—
Navann Ty68%
$27 → $30MaintainsBuyGet Alert
11/27/2012JAZZBuy Now
Jazz Pharmaceuticals
$106.90-34.52%
Navann Ty68%
→ $70Initiates → BuyGet Alert
04/10/2012JAZZBuy Now
Jazz Pharmaceuticals
$106.90-43.87%
Navann Ty68%
→ $60Initiates → BuyGet Alert

Recent Analyst Stock Rating News

The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.
Get Started for Free